PRECISION BIOSCIENCES INC
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $0 | $-1.26 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $10.80M | $-0.75 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | $34.20M | $1.05 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $100.00K | $-1.84 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-2.13 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $29.00K | $-2.21 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | Before market open | $600.00K | $-2.22 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | $600.00K | $-2.25 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
Press releases
Announcements Precision Biosciences filed with the SEC
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences PBGENE-DMD Investor Update March 17, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
Other events · EX-99.,1 to Form 8-K
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Agreement terminated · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
Other events · EX-99.1 to Form 8-K
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26 th Annual Meeting
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision BioSciences Announces Change to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision BioSciences Announces Senior Leadership Organizational Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K